Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Rituximab (MabThera®/Rituxan®) in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: PlaceboBiological: RituximabDrug: MethylprednisoloneDrug: MethotrexateDrug: Folic acid or folate
- First Posted Date
- 2007-12-21
- Last Posted Date
- 2015-04-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 185
- Registration Number
- NCT00578305
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.
Phase 4
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 60
- Registration Number
- NCT00576433
GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2014-08-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 175
- Registration Number
- NCT00576758
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.
Phase 2
Withdrawn
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00577109
A Study of Subcutaneous Mircera, Versus no Erythropoiesis-Stimulating Agent (ESA) Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant
Phase 4
Terminated
- Conditions
- Anemia
- Interventions
- Drug: methoxy polyethylene glycol-epoetin beta [Mircera]Drug: Supportive treatment
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1
- Registration Number
- NCT00576602
OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.
Phase 4
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2015-08-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 205
- Registration Number
- NCT00577031
A Study of Subcutaneous C.E.R.A. for the Treatment of Anemia in Pre-Dialysis Patients.
Phase 3
Completed
- Conditions
- Anemia
- Interventions
- Drug: methoxy polyethylene glycol-epoetin beta [C.E.R.A.]
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 133
- Registration Number
- NCT00576628
A Study of Intravenous Mircera in Dialysis Patients With Chronic Renal Disease and Anemia.
Phase 3
Completed
- Conditions
- Anemia
- Interventions
- Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 200
- Registration Number
- NCT00576303
A Study of Avastin (Bevacizumab) and Transarterial Chemoembolisation (TACE) Treatment in Patients With Liver Cancer
Phase 2
Completed
- Conditions
- Liver Cancer
- Interventions
- Drug: BevacizumabProcedure: Transarterial chemoembolisation (TACE)
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2014-08-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 30
- Registration Number
- NCT00576199
A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Docetaxel in Patients With Inflammatory or Locally Advanced Breast Cancer.
Phase 2
Terminated
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2014-08-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 23
- Registration Number
- NCT00576901
© Copyright 2025. All Rights Reserved by MedPath